Abstract

The utility of echo decorrelation imaging feedback for real-time control of in vivo ultrasound thermal ablation was assessed in rabbit liver with VX2 tumor. High-intensity focused ultrasound (HIFU) and unfocused (bulk) ablation were performed using 5 MHz linear image-ablate arrays. Treatments comprised up to nine lower-power sonications, followed by up to nine higher-power sonications, ceasing when the average cumulative echo decorrelation within a control region of interest exceeded a predefined threshold (− 2.3, log10-scaled echo decorrelation per millisecond, corresponding to 90% specificity for tumor ablation prediction in previous in vivo experiments). This threshold was exceeded in all cases for both HIFU (N = 12) and bulk (N = 8) ablation. Controlled HIFU trials achieved a significantly higher average ablation rate compared to comparable ablation trials without image-based control, reported previously. Both controlled HIFU and bulk ablation trials required significantly less treatment time than these previous uncontrolled trials. Prediction of local liver and VX2 tumor ablation using echo decorrelation was tested using receiver operator characteristic curve analysis, showing prediction capability statistically equivalent to uncontrolled trials. Compared to uncontrolled trials, controlled trials resulted in smaller thermal ablation regions and higher contrast between echo decorrelation in treated vs. untreated regions. These results indicate that control using echo decorrelation imaging may reduce treatment duration and increase treatment reliability for in vivo thermal ablation.

Highlights

  • Hepatocellular carcinoma (HCC) is the most common primary malignant tumor in liver, especially in patients with cirrhosis (70–90% of all cirrhosis patients) [1, 2]

  • The objective of this study was to investigate the feasibility of controlling in vivo US thermal ablation, including high-intensity focused ultrasound (HIFU) and unfocused US ablation, using motion-corrected echo decorrelation imaging feedback in rabbit liver and VX2 tumor

  • Tissue sectioning results revealed that 22 out 24 implanted VX2 tumors were successfully grown in two weeks

Read more

Summary

Introduction

Hepatocellular carcinoma (HCC) is the most common primary malignant tumor in liver, especially in patients with cirrhosis (70–90% of all cirrhosis patients) [1, 2]. The liver is one of the most common sites for secondary tumors, e.g. colorectal cancer liver metastases (CLM). Prevalence of CLM is affected by the incidence of colorectal cancer, the third most common. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Guided Therapy Systems/Ardent Sound provided salary support for one author (PGB) and provided research materials including custom-designed transducer arrays, associated electronics, and accessories, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of all authors are articulated in the ‘author contributions’ section

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call